Veracyte’s (VCYT) progress with the three long-term growth drivers exhibits robust growth potential for the upcoming quarters. The record volume growth of the Decipher Prostrate test instills optimism, supported by the distinct recognition from the NCCN (National Comprehensive Cancer Network). The Afirma GRID offering can help the company extend its reach into the endocrinology market. Meanwhile, declining biopharma revenues and macroeconomic issues are worries for Veracyte.In the past year, this Zacks Rank ...

A month has gone by since the last earnings report for Veracyte (VCYT) . Shares have added about 9.2% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Veracyte due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Veracyte's Q2 Earnings Top Estimates, '24 Sales View UpVera ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?Developed alongsi ...

After reaching an important support level, Veracyte, Inc. (VCYT) could be a good stock pick from a technical perspective. VCYT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer-term moving a ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style Scor ...

Have you been paying attention to shares of Veracyte (VCYT) ? Shares have been on the move with the stock up 27.4% over the past month. The stock hit a new 52-week high of $32.86 in the previous session. Veracyte has gained 18.3% since the start of the year compared to the 8.2% move for the Zacks Medical sector and the 6.2% return for the Zacks Medical - Instruments industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings ...

Veracyte (VCYT) delivered second-quarter 2024 adjusted diluted earnings of 30 cents per share, up a stupendous 150% from the year-ago period’s level. The reported figure beat the Zacks Consensus Estimate of a loss of 3 cents per share.RevenuesRevenues increased 26.7% year over year to $114.4 million, which outpaced the Zacks Consensus Estimate by 14%.Segmental DetailsTesting revenues totaled $107 million in the reported quarter, up 31% year over year. This rise was mainly due to increased Decipher and Affir ...

On Tuesday, Veracyte, Inc VCYT reported second-quarter sales of $114.43 million, up 27% year over year, beating the consensus of $100.3 million.Testing revenue was $107.0 million, an increase of 31%, driven by the strong performance of our Decipher Prostate and Afirma tests.Total test volume grew to 39,023, an increase of 23% compared to the second quarter of 2023.During the quarter, the company achieved a record Decipher Prostate test volume of close to 19,900 tests, driven by recently updated NCCN prostat ...

公司业务概况 - 公司主要提供前列腺癌(Decipher Prostate)、甲状腺癌(Afirma)、乳腺癌(Prosigna)和膀胱癌(Decipher Bladder)等诊断测试[112] - 公司通过两种补充的模式为全球市场提供服务,在美国提供实验室开发测试(LDT),在美国以外主要通过分销给实验室和医院提供测试[112] - 公司于2024年2月收购了MRD检测公司C2i,旨在扩大在患者癌症旅程中的作用,从提供早期决策支持转向跟踪患者治疗过程[112] 收入来源 - 公司收入主要来自Decipher Prostate和Afirma测试的销售,主要销售对象为美国医生[131] - 公司前三大客户为Medicare(31%)、UnitedHealthcare(14%)和其他客户(45%)[130] 收入确认 - 公司根据预期可收回金额确认收入,需要管理层做出重大判断[118][132] 研发投入 - 公司研发支出时间安排难以预测,可能会导致季度间费用波动[130] 收入增长驱动因素 - 公司收入增长取决于获得更多支付者的承保决定、扩大处方医生群体和现有客户的渗透率[116] 宏观经济风险 - 公司面临宏观经济因素的风险,如利率变化、通胀和汇率波动等[113][114] 财务数据分析 - 测试收入增长31%,主要由于测试量增加24%和平均销售价格上升5%[146] - 生物制药和其他收入下降22%,主要由于客户项目减少[149] - 产品收入下降6%,主要由于产品测试套件需求下降[148] - 测试成本占测试收入的比例有所下降,预计随着规模效应和工艺优化成本将进一步降低[23] - 研发投入增加28%,主要用于早期产品开发和临床试验[137] - 销售和营销费用下降7%,主要由于成本控制措施[138] - 管理费用增加26%,主要用于支持收入增长[139] - 其他收益大幅增加152%,主要由于汇兑收益增加[141] - 总体来看,公司业绩保持良好增长态势,毛利率和净利率均有所提升[143,144] 成本分析 - 测试收入成本增加4.6百万美元,增长20%[152] - 测试收入成本增加10.9百万美元,增长25%[153] - 产品收入成本减少0.4百万美元,下降19%[154] - 生物制药及其他收入成本减少0.2百万美元和1.8百万美元[155] - 研发费用增加3.9百万美元,增长31%[158] - 研发费用增加7.1百万美元,增长28%[159] - 销售和营销费用减少1.5百万美元,下降6%[162] - 销售和营销费用减少3.9百万美元,下降7%[164] - 一般及行政费用增加6.7百万美元,增长27%[167] - 公司一般及行政费用较2023年同期增加1190万美元[168] 资产负债分析 - 2024年6月30日六个月内无长期资产减值[169] - 其他收益净额较2023年同期增加300万美元,主要由于利息收入增加140万美元和法国研发税收抵免增加180万美元[170][171] - 公司2024年和2023年6月30日三个月和六个月内分别计提160万美元和10万美元的所得税费用[172] - 公司预计未来两年内可能会撤销部分递延税资产的估值准备,从而产生所得税收益[173] - 截至2024年6月30日,公司现金及现金等价物为2.359亿美元,较2023年末增加1950万美元[174] - 公司预计未来12个月内现有现金及经营活动现金流将满足其现金需求[175] - 公司在2024年6月30日新租赁了一处位于法国马赛的设施,租赁期12年,年租金约130万美元[177] - 公司可能需要支付最多2500万美元的或有对价,其中500万美元预计将在未来12个月内支付[178][179]

财务数据和关键指标变化 - 第二季度收入为1.144亿美元,同比增长27% [25] - 检测业务收入增长31%,超出预期 [25] - 第二季度测试量约39,000份,同比增长23% [25] - 检测业务毛利率为74%,同比提升250个基点,主要由于ASP改善和前期现金收款 [27][28] - 产品毛利率为52%,受到有利的制造成本变动影响 [28] - 非GAAP经营利润率为21%,创历史新高,朝着25%的目标稳步前进 [34] - 经营活动产生的现金流为2,960万美元 [35] - 现金和现金等价物余额为2.359亿美元 [35] 各条业务线数据和关键指标变化 - Decipher Prostate检测量同比增长32%,创历史新高,达到19,900份 [14] - Afirma检测量同比增长17%,创历史新高,达到15,700份 [19] - Afirma GRID被约一半的医生选择使用,显示出医生对研究的浓厚兴趣 [20] 各个市场数据和关键指标变化 - Decipher Prostate在NCCN指南中获得最高证据等级,进一步推动了市场渗透 [15] - Afirma在Bethesda 5甲状腺结节患者中获得Medicare和Medicare Advantage的报销覆盖,预计每年可覆盖约10,000名患者 [21] 公司战略和发展方向及行业竞争 - 公司专注于5大战略重点:Decipher持续增长、Afirma持续增长、多个IVD产品的全球推广、解决新的癌症挑战、服务更多的患者旅程 [10][11] - 公司提交了Prosigna nCounter测试用于IVDR认证,这是未来IVD产品在全球推广的基础性工作 [10] - 公司正在开展NIGHTINGALE临床试验,以解决新的癌症挑战 [11] - 公司正在开发首个肌肉浸润性膀胱癌的最小残留病灶(MRD)检测,利用公司的全基因组平台 [11] 管理层对经营环境和未来前景的评论 - 公司独特的Veracyte诊断平台是强劲业绩和高增长的关键 [12][13] - 公司有信心Decipher和Afirma能够实现持续的收入增长 [22][23] - 公司预计2024年总收入将达4.32-4.38亿美元,较之前指引大幅上调 [36] - 公司预计2024年底现金和现金等价物将达2.6-2.7亿美元 [36] 问答环节重要的提问和回答 问题1 **Mason Carrico 提问** 一旦Decipher转移支付LCD最终确定,公司还需要采取哪些步骤,并预计需要多长时间? [40][41][42][43] **Marc Stapley 和 Rebecca Chambers 回答** 公司需要完成技术评估、培训销售团队、建立结算流程等,预计这些工作将在2025年完成,不会在2024年体现 [41][42][43] 问题2 **Yuko Oku 提问** 鉴于知识产权纠纷日益突出,公司的MRD组合策略会受到什么影响?公司是否会参与类似Personalis和Myriad之间的专利池共享? [52][53][54] **Marc Stapley 回答** 公司收购C2i业务时就考虑到了知识产权自由运营的问题,采用了基于全基因组的方法,这种方法相比针对性方法有更大的自由度。公司目前没有参与专利池共享的计划 [53][54] 问题3 **Prashant Kota 提问** 公司如何看待Afirma ASP的走势,考虑到GRID和Bethesda V分类的影响? [81][82][83][84] **Marc Stapley 和 Rebecca Chambers 回答** GRID目前仍然是研究用途,不会成为临床用途。Bethesda V分类的影响有限,但是与Decipher ASP改善等因素共同推动了过去两年5%的Afirma ASP复合年增长率 [82][83][84]